Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Protalix BioTherapeutics
So what: Gaucher disease drugs marketed by Genzyme
Now what: Today's 20%-plus sell-off looks to be a tad overdone. Protalix said that it plans to work closely with its gorilla co-developer Pfizer
Interested in more info on Protalix? Add it to your watchlist.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.